Literature DB >> 25901415

A vaccine against Ebola: Problems and opportunities.

Giovanni Rezza1.   

Abstract

The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3 West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1 studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola.

Entities:  

Keywords:  Ebola; epidemiology; ethics; study design; vectored vaccine

Mesh:

Substances:

Year:  2015        PMID: 25901415      PMCID: PMC4514158          DOI: 10.1080/21645515.2015.1021528

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

3.  Ebola vaccine trials back on track.

Authors:  Dara Mohammadi
Journal:  Lancet       Date:  2015-01-17       Impact factor: 79.321

4.  Infectious Disease. Ebola vaccines racing forward at record pace.

Authors:  Jon Cohen
Journal:  Science       Date:  2014-09-12       Impact factor: 47.728

5.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Authors:  Daphne A Stanley; Anna N Honko; Clement Asiedu; John C Trefry; Annie W Lau-Kilby; Joshua C Johnson; Lisa Hensley; Virginia Ammendola; Adele Abbate; Fabiana Grazioli; Kathryn E Foulds; Cheng Cheng; Lingshu Wang; Mitzi M Donaldson; Stefano Colloca; Antonella Folgori; Mario Roederer; Gary J Nabel; John Mascola; Alfredo Nicosia; Riccardo Cortese; Richard A Koup; Nancy J Sullivan
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

6.  Infectious disease. Ebola vaccine: little and late.

Authors:  Jon Cohen
Journal:  Science       Date:  2014-09-19       Impact factor: 47.728

7.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

8.  Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.

Authors:  Hannah Kibuuka; Nina M Berkowitz; Monica Millard; Mary E Enama; Allan Tindikahwa; Arthur B Sekiziyivu; Pamela Costner; Sandra Sitar; Deline Glover; Zonghui Hu; Gyan Joshi; Daphne Stanley; Meghan Kunchai; Leigh Anne Eller; Robert T Bailer; Richard A Koup; Gary J Nabel; John R Mascola; Nancy J Sullivan; Barney S Graham; Mario Roederer; Nelson L Michael; Merlin L Robb; Julie E Ledgerwood
Journal:  Lancet       Date:  2014-12-23       Impact factor: 79.321

9.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Authors:  Katie Ewer; Tommy Rampling; Navin Venkatraman; Georgina Bowyer; Danny Wright; Teresa Lambe; Egeruan B Imoukhuede; Ruth Payne; Sarah Katharina Fehling; Thomas Strecker; Nadine Biedenkopf; Verena Krähling; Claire M Tully; Nick J Edwards; Emma M Bentley; Dhanraj Samuel; Geneviève Labbé; Jing Jin; Malick Gibani; Alice Minhinnick; Morven Wilkie; Ian Poulton; Natalie Lella; Rachel Roberts; Felicity Hartnell; Carly Bliss; Kailan Sierra-Davidson; Jonathan Powlson; Eleanor Berrie; Richard Tedder; Francois Roman; Iris De Ryck; Alfredo Nicosia; Nancy J Sullivan; Daphne A Stanley; Olivier T Mbaya; Julie E Ledgerwood; Richard M Schwartz; Loredana Siani; Stefano Colloca; Antonella Folgori; Stefania Di Marco; Riccardo Cortese; Edward Wright; Stephan Becker; Barney S Graham; Richard A Koup; Myron M Levine; Ariane Volkmann; Paul Chaplin; Andrew J Pollard; Simon J Draper; W Ripley Ballou; Alison Lawrie; Sarah C Gilbert; Adrian V S Hill
Journal:  N Engl J Med       Date:  2015-01-28       Impact factor: 91.245

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

View more
  1 in total

1.  An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.

Authors:  C V Herst; S Burkholz; J Sidney; A Sette; P E Harris; S Massey; T Brasel; E Cunha-Neto; D S Rosa; W C H Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Journal:  Vaccine       Date:  2020-04-28       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.